Spliceosome mutations are common in MPN-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide

Spliceosome mutations are common in MPN-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide

書誌詳細
主要な著者:	Chowdhury, O, O'Sullivan, J, Barkas, N, Buck, G, Hamblin, A, Tefferi, A, Al-Ali, H, Barosi, G, Devos, T, Gisslinger, H, Jiang, Q, Kiladjian, J, Mesa, R, Passamonti, F, Ribrag, V, Schiller, G, Vannucchi, A, Zhou, D, McMullin, M, Reiser, D, Zhong, J, Gale, R, Mead, A
フォーマット:	Conference item
出版事項:	American Society of Hematology 2018

類似資料

Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide
著者:: Chowdhury, O, 等
出版事項: (2020)

Profile of pomalidomide and its potential in the treatment of myelofibrosis
著者:: Gowin KL, 等
出版事項: (2015-04-01)

The UK Myeloproliferative Neoplasm Registry for Myelofibrosis (UK-MPN-MF registry)
著者:: Butt, N, 等
出版事項: (2019)

Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach
著者:: Alessandra Carobbio, 等
出版事項: (2023-07-01)

P1041: IMPACT OF FEDRATINIB ON SPLEEN VOLUME AND MYELOFIBROSIS SYMPTOMS IN PATIENTS WITH SUBSTANTIAL SPLENOMEGALY: POST HOC ANALYSES FROM THE JAKARTA AND JAKARTA2 TRIALS
著者:: J.-J. Kiladjian, 等
出版事項: (2022-06-01)

Clonal evolution: a landmark of MPN evolution
著者:: Nabih Maslah, 等
出版事項: (2024-10-01)

A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis
著者:: Claire Harrison, 等
出版事項: (2022-08-01)

P1055: CLINICAL AND GENETIC RESULTS OF THE PHASE IB/II TRIAL MPNSG-0212: RUXOLITINIB PLUS POMALIDOMIDE IN MYELOFIBROSIS WITH ANEMIA
著者:: F. Stegelmann, 等
出版事項: (2022-06-01)

Primary myelofibrosis and its paraneoplastic stromal effects
著者:: Ayalew Tefferi
出版事項: (2007-05-01)

P1037: DOES EARLY INTERVENTION IN MYELOFIBROSIS IMPACT OUTCOMES? A POOLED ANALYSIS OF THE COMFORT I AND II STUDIES
著者:: C. Harrison, 等
出版事項: (2022-06-01)

European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica 2012;97(3):360–5 - Comment
著者:: Jürgen Thiele, 等
出版事項: (2012-03-01)

Patterns of conservation of spliceosomal intron structures and spliceosome divergence in representatives of the diplomonad and parabasalid lineages
著者:: Andrew J. Hudson, 等
出版事項: (2019-08-01)

S198: BET INHIBITOR PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS — JAK INHIBITOR-NAÏVE OR WITH SUBOPTIMAL RESPONSE TO RUXOLITINIB — PRELIMINARY DATA FROM THE MANIFEST STUDY
著者:: J. Mascarenhas, 等
出版事項: (2022-06-01)

UK results from the myeloproliferative neoplasms (MPN) landmark survey on the symptom, emotional and economic burden of MPN
著者:: Harrison, C, 等
出版事項: (2019)

The Gordian knot: ruxolitinib or transplants for high-risk myelofibrosis
著者:: Robert Peter Gale, 等
出版事項: (2024-07-01)

Incidence of blast phase in myelofibrosis according to anemia severity
著者:: Barbara Mora, 等
出版事項: (2023-08-01)

Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry
著者:: A. Kaifie, 等
出版事項: (2016-03-01)

Mpn-238 single-cell RNA profiling of myelofibrosis patients reveals pelabresib-induced decrease of megakaryocytic progenitors and normalization of CD4+ T cells in peripheral blood
著者:: Zavidij, O, 等
出版事項: (2022)

Pomalidomide-induced hypothyroidism
著者:: Sulaiman Haji Ali, 等
出版事項: (2017-12-01)

S167: EFFICACY AND SAFETY OF LUSPATERCEPT FOR THE TREATMENT OF ANEMIA IN PATIENTS WITH MYELOFIBROSIS: RESULTS FROM THE ACE-536-MF-001 STUDY
著者:: Aaron T. Gerds, 等
出版事項: (2023-08-01)

Guideline for the diagnosis and management of myelofibrosis
著者:: Reilly, J, 等
出版事項: (2012)

Guideline for the diagnosis and management of myelofibrosis.
著者:: Reilly, J, 等
出版事項: (2012)

Chromothripsis orchestrates leukemic transformation in blast phase MPN through targetable amplification of DYRK1A
著者:: Brierley, CK, 等
出版事項: (2023)

Thrombosis in myeloproliferative neoplasms: a viewpoint on its impact on myelofibrosis, mortality, and solid tumors
著者:: Tiziano Barbui, 等
出版事項: (2024-10-01)

MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic
著者:: Verstovsek, S, 等
出版事項: (2021)

MPN Membangun Negara
著者:: Ishak, Mohamed Mustafa
出版事項: (2010)

Pomalidomide-dexamethasone in the management of heavily pretreated multiple myeloma
著者:: C. Cerchione, 等
出版事項: (2020-10-01)

P1069: RETROSPECTIVE COMPARISON OF PATIENT OUTCOMES ON PACRITINIB VERSUS RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS AND THROMBOCYTOPENIA
著者:: C. Harrison, 等
出版事項: (2022-06-01)

Low-dose thalidomide in myelofibrosis
著者:: Robert Weinkove, 等
出版事項: (2008-07-01)

Use of JAK inhibitors in the management of myelofibrosis: A revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012
著者:: Reilly, J, 等
出版事項: (2014)

Prognostic relevance of anemia and transfusion dependency in myelodysplastic syndromes and primary myelofibrosis
著者:: Animesh Pardanani, 等
出版事項: (2011-01-01)

Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012.
著者:: Reilly, J, 等
出版事項: (2014)

P1009: PREDICTORS OF HOSPITALIZATION AND SEVERE OUTCOMES IN PATIENTS WITH MPN AND COVID-19
著者:: T. Barbui, 等
出版事項: (2022-06-01)

P1029: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PELABRESIB (CPI-0610) IN COMBINATION WITH RUXOLITINIB VS RUXOLITINIB OR FEDRATINIB MONOTHERAPY IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
著者:: V. Gupta, 等
出版事項: (2022-06-01)

Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial
著者:: Claire N. Harrison, 等
出版事項: (2021-05-01)

Mutational spectrum defines primary and secondary myelofibrosis
著者:: Ken I. Mills, 等
出版事項: (2014-01-01)

Breakthrough infections in MPN-COVID vaccinated patients
著者:: Tiziano Barbui, 等
出版事項: (2022-11-01)

Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib
著者:: Ruben Mesa, 等
出版事項: (2023-06-01)

Standard care and investigational drugs in the treatment of myelofibrosis
著者:: Daniela Barraco, 等
出版事項: (2019-09-01)

Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia
著者:: Srdan Verstovsek, 等
出版事項: (2021-09-01)